Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are already taking part in the PREVALUNG or PREVALUNG ETOILE studies
- Active or former smokers aged 45–75 who smoked daily for at least 10 years and have been diagnosed with a disease affecting the arteries (such as those supplying the heart, legs, or other organs), or who have a moderate or high calcium build-up score in the arteries around the heart (as measured on a chest scan)
- People aged 45–75 who smoked daily for at least 10 years and are being treated for a smoking-related lung condition such as chronic bronchitis or emphysema
- People aged 45–75 who smoked daily for at least 10 years and have a history of cancer that has not been active for more than 5 years (including certain cancers of the head and neck, lung, breast, cervix, bladder, digestive system, kidney, or blood)
- People meeting the NLST study criteria: aged 55–74, with a smoking history of at least 30 pack-years, and either currently smoking or having stopped within the last 15 years (confirm with trial site)
- People meeting the NELSON study criteria: aged 50–75 and having smoked more than 15 cigarettes a day for over 25 years, or more than 10 cigarettes a day for over 30 years, and either currently smoking or having stopped within the last 10 years
- People meeting US guideline criteria: aged 50–80 with a smoking history of at least 20 pack-years (confirm with trial site)
Who may not be able to join:
- People diagnosed with cancer within the last 5 years (with some exceptions, including certain non-invasive skin, cervical, bladder, or prostate cancers — confirm with trial site)
- People experiencing symptoms that may suggest lung cancer, such as losing more than 7 kg in weight without trying, or coughing up blood
- People with a known lung nodule that already requires specialist monitoring
- People with a history of pulmonary fibrosis (scarring of the lungs) or high blood pressure in the lungs
- People with an active infection in the lung tissue
- People with severe heart or breathing problems that cause breathlessness at rest
- People with a reduced ability to carry out daily activities, rated at level 2, 3, or 4 on the WHO performance scale (confirm with trial site)
- People who are not covered by the French social security system
- People who are currently detained or under a legal order restricting their freedom
- People who are under legal guardianship or trusteeship
- Women who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mathilde LEFEVRE, ASSISTANCEPUBLIQUE HOPTAUX DE MARSEILLE
Phone: 491381245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
biomarker group validation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.